We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




New Reagent Aids in Diagnosis of Connective Tissue Disease in Hard-to-Detect Autoimmune Conditions

By LabMedica International staff writers
Posted on 19 Oct 2023
Print article
Image: The Aptiva Connective Tissue Disease Essential reagent has received US FDA 510(K) clearance (Photo courtesy of Werfen)
Image: The Aptiva Connective Tissue Disease Essential reagent has received US FDA 510(K) clearance (Photo courtesy of Werfen)

The increasing incidence of autoimmune diseases like rheumatoid arthritis, lupus, and multiple sclerosis has created great demand for accurate and reliable diagnostic methods. As patients become more knowledgeable about the symptoms and risks of these diseases, they are seeking quicker testing solutions for early detection and management. Reagents and consumables are a key component in the diagnostic process of autoimmune disorders. Now, a new reagent can aid in the diagnosis of connective tissue disease in hard-to-diagnose autoimmune diseases, thus speeding up diagnosis and enhancing patient outcomes.

Werfen (Barcelona, Spain) has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Aptiva Connective Tissue Disease (CTD) Essential reagent. This product complements the company's already FDA-approved Aptiva Celiac Disease reagent. Apart from CTD and Celiac Disease tests, Aptiva is working on diagnostics for other autoimmune conditions and has more than 60 analytes at different stages of advanced development. These analytes have the capability to shorten the diagnostic time for autoimmune diseases and contribute to more effective patient care.

The Aptiva system is a fully automated multi-analyte platform that marks the next generation of high-throughput multi-analyte systems for clinical autoimmune labs. This system employs particle-based multi-analyte technology (PMAT) which simultaneously processes multiple analytes using a single patient sample. Thanks to PMAT, the Aptiva CTD Essential reagent can yield of up to 600 results per hour and enable labs to handle their testing volumes with minimal hands-on time.

"Aptiva CTD Essential with its unique biomarker composition and high level of analytical and clinical performance represents a breakthrough that fundamentally enhances the utility of diagnostic testing in the autoimmune laboratory," said Michael Mahler, PhD, Vice President of Research and Business Development at Werfen. "We are excited to bring this latest expansion of the Aptiva reagent menu to the US market, resulting in advanced patient care."

Related Links:
Werfen 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: Molecular PCR-grade detection of Lyme bacteria right at the tick bite (Photo courtesy of En Carta Diagnostics)

Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes

Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations,... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.